Widely used:Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$5,497 Mln
P/E Ratio
47.34
P/B Ratio
3.09
Industry P/E
--
Debt to Equity
1.24
ROE
0.07 %
ROCE
3.35 %
Div. Yield
0.56 %
Book Value
11.72
EPS
0.74
CFO
$2,309.50 Mln
EBITDA
$3,741.20 Mln
Net Profit
$1,926.10 Mln
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|
|---|---|---|---|---|---|---|---|
|
Bruker (BRKR)
| -35.36 | -14.76 | -36.98 | -51.45 | -13.74 | 1.37 | 6.93 |
|
BSE Sensex*
| 1.99 | 3.77 | 4.29 | 8.22 | 11.74 | 20.16 | 11.15 |
|
S&P Small-Cap 600#
| -5.82 | -5.34 | -13.73 | -6.30 | 5.30 | 2.98 | 5.53 |
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
2018
|
|
|---|---|---|---|---|---|---|---|
|
Bruker (BRKR)
| -20.08 | 7.51 | -18.54 | 55.02 | 6.20 | 71.21 | -13.19 |
|
S&P Small-Cap 600
| 7.01 | 13.89 | -17.42 | 25.27 | 9.57 | 20.86 | -9.70 |
|
BSE Sensex
| 8.10 | 18.74 | 4.44 | 21.99 | 15.75 | 14.38 | 5.87 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
3Y Avg -- 5Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | P/E Ratio | ROE |
|---|---|---|---|---|
| 15.47 | 10,289.47 | 14.38 | 12.69 | |
| 71.79 | 9,544.04 | 92.52 | 2.52 | |
| 157.93 | 8,064.21 | -- | -25.23 | |
| 278.77 | 10,728.90 | 773.26 | 1.2 |
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates... through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts. Address: 40 Manning Road, Billerica, MA, United States, 01821 Read more
Chairman, CEO & President
Dr. Frank H. Laukien Ph.D.
Chairman, CEO & President
Dr. Frank H. Laukien Ph.D.
Headquarters
Billerica, MA
Website
Our rating system has guided millions of investors in the past 20 years.
The total asset value of Bruker Corporation (BRKR) stood at $ 5,807 Mln as on 31-Dec-24
The share price of Bruker Corporation (BRKR) is $37.89 (NASDAQ) as of 23-Apr-2025 16:00 EDT. Bruker Corporation (BRKR) has given a return of -13.74% in the last 3 years.
Bruker Corporation (BRKR) has a market capitalisation of $ 5,497 Mln as on 22-Apr-2025. As per Value Research classification, it is a Small Cap company.
The P/E ratio of Bruker Corporation (BRKR) is 47.34 times as on 22-Apr-2025.
Step 1. Open a demat account through a broker. You would need to provide your email, PAN, bank account details, aadhar details, etc., for KYC
Step 2. Sign in to the broker’s application through a mobile app or website. Use the Login ID and password provided by your broker.
Step 3. Transfer funds from your bank account into the wallet present in your brokerage account.
Step 4. Search for the Bruker Corporation (BRKR) and enter the required number of quantities and click on buy to purchase the shares of Bruker Corporation (BRKR).
Bruker Corporation, together with its subsidiaries, develops, manufactures, and distributes scientific instruments, and analytical and diagnostic solutions in the United States, Europe, the Asia Pacific, and internationally. The company operates through four segments: Bruker Scientific Instruments (BSI) BioSpin, BSI CALID, BSI Nano, and Bruker Energy & Supercon Technologies. It offers magnetic resonance spectroscop, preclinical imaging, biopharma and applied, services and lifecycle support, integrated data solution, and automation; life science tools, and single and multiple modality systems; life science mass spectrometry; MALDI Biotyper platform for bacterial and fungal identification and establish, DNA test strips, and; genotype and fluorotype molecular diagnostics kits; and research, analytical, and process analysis instruments and solutions. It provides range of portable analytical and bioanalytical detection systems, and related products; X-ray instruments; analytical tools for electron microscopes, as well as handheld, portable, and mobile X-ray fluorescence spectrometry instruments; atomic force microscopy instrumentation; non-contact nanometer resolution solution topography; and automated X-ray metrology, automated AFM defect-detection, and photomask repair and cleaning equipment. In addition, the company offers advanced optical fluorescence microscopy instruments; products and services to support the multi-omics needs of researchers in translational research, drug, and biomarker discovery; superconducting materials, such as metallic low temperature superconductors; devices and complex tools based on metallic low temperature superconductors; and non-superconducting high technology tools, such as synchrotron and beamline instrumentation. The company was founded in 1960 and is headquartered in Billerica, Massachusetts. Address: 40 Manning Road, Billerica, MA, United States, 01821
The CEO & director of Dr. Frank H. Laukien Ph.D.. is Bruker Corporation (BRKR), and CFO & Sr. VP is Dr. Frank H. Laukien Ph.D..
There is no promoter pledging in Bruker Corporation (BRKR).
Some of the close peers are:
| Company | Market Cap($ Mln) |
|---|---|
|
1,070
|
|
|
1,049
|
|
|
978
|
|
|
820
|
| Bruker Corporation (BRKR) | Ratios |
|---|---|
|
Return on equity(%)
|
7.16
|
|
Operating margin(%)
|
7.57
|
|
Net Margin(%)
|
3.36
|
|
Dividend yield(%)
|
--
|
No, TTM profit after tax of Bruker Corporation (BRKR) was $0 Mln.
$0.93
(
